S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:HALO

Halozyme Therapeutics News Headlines

$40.41
-1.52 (-3.63 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.35
Now: $40.41
$42.44
50-Day Range
$41.93
MA: $48.17
$51.45
52-Week Range
$12.71
Now: $40.41
$56.40
Volume1.90 million shs
Average Volume1.53 million shs
Market Capitalization$5.47 billion
P/E Ratio252.56
Dividend YieldN/A
Beta1.77

Headlines

Halozyme Therapeutics (NASDAQ HALO) News Headlines Today

Source:
SourceHeadline
 Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Earnings of $0.32 Per Share Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Earnings of $0.32 Per Share
americanbankingnews.com - March 4 at 10:16 PM
Lets Take Another Look at Halozyme TherapeuticsLet's Take Another Look at Halozyme Therapeutics
finance.yahoo.com - March 4 at 5:09 PM
2 Overvalued Biotech Stocks Still Worth Buying2 Overvalued Biotech Stocks Still Worth Buying
finance.yahoo.com - March 4 at 7:04 AM
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 6.8%Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 6.8%
americanbankingnews.com - March 3 at 8:06 PM
Helen Torley Sells 50,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockHelen Torley Sells 50,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
americanbankingnews.com - March 1 at 10:04 PM
Michael J. Labarre Sells 18,324 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockMichael J. Labarre Sells 18,324 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
americanbankingnews.com - March 1 at 10:04 PM
Kenneth J. Kelley Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockKenneth J. Kelley Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
americanbankingnews.com - March 1 at 9:32 PM
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8%Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8%
americanbankingnews.com - February 25 at 9:18 PM
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
finance.yahoo.com - February 24 at 11:11 PM
Why Halozyme Therapeutics Is Trading 14% Higher TodayWhy Halozyme Therapeutics Is Trading 14% Higher Today
fool.com - February 24 at 3:45 PM
Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock FallsHalozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls
nasdaq.com - February 24 at 1:10 PM
Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High at $55.55Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High at $55.55
americanbankingnews.com - February 24 at 11:01 AM
Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call TranscriptHalozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript
fool.com - February 23 at 10:44 PM
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 ResultsHalozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
finance.yahoo.com - February 23 at 7:55 PM
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
finance.yahoo.com - February 23 at 7:55 PM
Recap: Halozyme Therapeutics Q4 EarningsRecap: Halozyme Therapeutics Q4 Earnings
finance.yahoo.com - February 23 at 7:55 PM
Halozyme Therapeutics, Inc. 2020 Q4 - Results - Earnings Call PresentationHalozyme Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 23 at 7:34 PM
Halozyme Therapeuticss Earnings: A PreviewHalozyme Therapeutics's Earnings: A Preview
finance.yahoo.com - February 22 at 1:30 PM
Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference CallHalozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
finance.yahoo.com - February 10 at 5:57 PM
Antidiabetics Market (Impact of COVID-19) Size, Status and Forecast 2020-2025Antidiabetics Market (Impact of COVID-19) Size, Status and Forecast 2020-2025
marketwatch.com - February 9 at 8:01 PM
Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High at $51.28Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High at $51.28
americanbankingnews.com - February 9 at 10:44 AM
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) AmyloidosisHalozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis
finance.yahoo.com - January 16 at 4:20 AM
First Week of September 17th Options Trading For Halozyme Therapeutics (HALO)First Week of September 17th Options Trading For Halozyme Therapeutics (HALO)
nasdaq.com - January 15 at 12:50 PM
Regeneron (REGN), U.S. Government Ink Deal for COVID-19 TreatmentRegeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment
finance.yahoo.com - January 13 at 6:12 PM
Sarepta (SRPT) Looks Good: Stock Adds 9.1% in SessionSarepta (SRPT) Looks Good: Stock Adds 9.1% in Session
msn.com - January 12 at 1:42 PM
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS GrowthHalozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
finance.yahoo.com - January 11 at 9:57 AM
Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare ConferenceHalozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:18 AM
A Technical Update on Halozyme TherapeuticsA Technical Update on Halozyme Therapeutics
finance.yahoo.com - December 23 at 4:05 PM
Breast Cancer Therapeutics Drugs Market 2021 Growth After Covid-19 Pandemic with Top Manufacturers: Bayer HealthCare, Eli Lily, PfizerBreast Cancer Therapeutics Drugs Market 2021 Growth After Covid-19 Pandemic with Top Manufacturers: Bayer HealthCare, Eli Lily, Pfizer
benzinga.com - December 22 at 8:49 AM
Is Halozyme Therapeutics, Inc.s (NASDAQ:HALO) 22% ROE Better Than Average?Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) 22% ROE Better Than Average?
finance.yahoo.com - December 19 at 12:45 PM
Why These 3 Health Care Stocks Are Moving TodayWhy These 3 Health Care Stocks Are Moving Today
benzinga.com - December 17 at 1:47 PM
Halozyme Therapeutics (NASDAQ:HALO) Now Covered by Analysts at Berenberg BankHalozyme Therapeutics (NASDAQ:HALO) Now Covered by Analysts at Berenberg Bank
americanbankingnews.com - December 17 at 8:44 AM
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
finance.yahoo.com - December 16 at 1:46 PM
Viatris (VTRS) to Cut Jobs as Part of Restructuring InitiativeViatris (VTRS) to Cut Jobs as Part of Restructuring Initiative
finance.yahoo.com - December 14 at 5:41 PM
Exelixis (EXEL) In-Licenses Aurigenes Compound, Files INDExelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
finance.yahoo.com - December 8 at 4:35 PM
Halozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions To AnswerHalozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions To Answer
seekingalpha.com - December 7 at 2:48 AM
Halozyme Therapeutics Is Likely to Continue Its AdvanceHalozyme Therapeutics Is Likely to Continue Its Advance
finance.yahoo.com - December 4 at 5:11 PM
Why Is Halozyme Therapeutics (HALO) Up 28.4% Since Last Earnings Report?Why Is Halozyme Therapeutics (HALO) Up 28.4% Since Last Earnings Report?
finance.yahoo.com - December 2 at 4:58 PM
What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now?What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now?
finance.yahoo.com - November 27 at 1:47 PM
A Look Into Halozyme Therapeuticss DebtA Look Into Halozyme Therapeutics's Debt
finance.yahoo.com - November 23 at 1:52 PM
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE ® TechnologyHorizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE ® Technology
businesswire.com - November 23 at 8:51 AM
Halozyme raises FY20 guidance on Horizon Therapeutics global collaborationHalozyme raises FY20 guidance on Horizon Therapeutics global collaboration
seekingalpha.com - November 23 at 8:51 AM
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® TechnologyHorizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
finance.yahoo.com - November 23 at 8:51 AM
Halozyme Raises Full Year 2020 GuidanceHalozyme Raises Full Year 2020 Guidance
finance.yahoo.com - November 23 at 8:51 AM
Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare ConferenceHalozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 18 at 8:44 PM
Wells Fargo Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $60Wells Fargo Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $60
benzinga.com - November 17 at 10:54 PM
Thinking about trading options or stock in Ford, Draftkings, Li Auto, Vipshop Holdings, or Halozyme Therapeutics?Thinking about trading options or stock in Ford, Draftkings, Li Auto, Vipshop Holdings, or Halozyme Therapeutics?
prnewswire.com - November 13 at 1:13 PM
Halozyme Announces CHMP Recommends EU Approval Of Roches Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozymes ENHANZE® Technology For HER2-Positive Breast CancerHalozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer
finance.yahoo.com - November 13 at 1:13 PM
Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple MyelomaHalozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
finance.yahoo.com - November 12 at 1:09 PM
Stock Alert: Halozyme Therapeutics Gains 10%Stock Alert: Halozyme Therapeutics Gains 10%
nasdaq.com - November 6 at 1:33 PM
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.